engleski

Strawberry tree (Arbutus unedo L.) honey extract ameliorates genotoxic effects of irinotecan but leads to cell cycle delays in human peripheral lymphocytes in vitro

This study assessed genotoxic profile of strawberry tree honey extract (STHE) (i.e. extracted phenolic fraction of STH) and its potential protective effects against cytogenetic damage induced by the anticancer drug irinotecan (IRI) in human peripheral lymphocytes in vitro. Isolated lymphocytes were exposed for 2 h to three different concentrations of STHE (corresponding to average daily portion of 50 g of honey, as well as five- and ten- fold higher concentration) alone and in combination with IRI. Concentration of IRI corresponded to its therapeutic dose of 350 mg/m2. The outcomes of the treatments were evaluated using the analysis of chromosomal aberrations and the cytokinesis-block micronucleus (CBMN) cytome assay. Although STHE increased incidence of chromosomal aberrations compared to negative control at all tested concentrations, when administered with IRI, it showed significant protective effects. Single STHE did not produce significant changes in number of MN and nuclear buds (NB) compared to negative control. When given in combination with tested anticancer drug, STHE effectively diminished incidence of both MN and NB compared to single IRI. The most prominent effect of STHE observed both after single and combined treatments was its cell- cycle delaying activity, which resulted with significantly lowered values of the replication index. Observed cytostatic effect could be associated with chemical composition of the tested extract, whose constituents exhibited both prooxidative and antioxidative properties. Convincing results obtained in vitro speak in favour of future investigations of STH, and further development of STH-based nutraceuticals, potentially useful even in cancer patients.

chromosomal aberrations, micronucleus assay, cyto-/genoprotective effects, lymphocytes

nije evidentirano